In response to the ongoing COVID-19 pandemic, on Jan 21, 2021 Erba launched the ErbaMDx SARS-CoV-2 RT-PCR Kit for detection of SARS-CoV-2.

To overcome challenges in older COVID-19 molecular tests, Erba's Cambridge(UK)-based development team has carefully engineered a new assay to improve detection and ease of use with a single tube multiplex mastermix, compatible with room-temperature storage and transportation.

The new assay offers 200 copies/ml LoD, using universally trusted gene targets highly specific for SARS-CoV-2 and updated primer sequences to maximise long term performance. Sample types include both nasopharyngeal and oropharyngeal swabs as well as saliva.

Nikhil Vazirani, MD of Erba, said: "We are proud and excited to add a highly sensitive RT-PCR test to our growing range of immunoassay and molecular solutions. The new ErbaMDx SARS-CoV-2 test perfectly complements our successful COVID-19 IgG and IgM ELISA assays to offer customers a state-of-the-art molecular test in addition to antibody testing which will offer clinicians valuable insight into the immune response to infection or vaccination."

The CE-marked kit will be available through Erba's global distribution network.

Erba was founded in 1979 as Transasia Bio-Medicals Ltd. by Suresh Vazirani who recognized the need for dedicated healthcare solutions for developing nations after witnessing the short comings of the healthcare systems in his home country India.